<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-126487</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Clinical experience and peritoneal clearance with icodextrin. Multicenter study</dc:title>
<dc:description xml:lang="en">The aim of this study was to analyse our experience with icodextrin in Andalusia, Spain. The study includes 51 patients (30 women and 21 men) on peritoneal dialysis (21 on CAPD and 30 on Automated Peritoneal Dialysis) treated with icodextrin for 10.3 ± 7 months (0-41 months). Their mean age was 57 ± 18 years(18-86 years). We have recorded the appearance of side effects, and the evolu(18-86 years). We have recorded the appearance of side effects, and the evolution of several biochemical parameters at baseline and after 6, 12 ans 18 months from initiation of icodextrin. We also studied drainage fluid from 12 patients after an icodextrin exchange. Results: There were side effects (all cutaneous) in 4 out of 51 patients (7,8%).Two of the affected suffered from cutaneous hypersensitivity reactions, and icodextrin had to be suspended; the other two had exfoliative dermatitis affecting hands and feet that disappeared without have to withdraws icodextrin. Biochemical parameters: Serum sodium levels decreased from baseline to six months (138 ± 6 mEq/l vs 136 ± 3 mEq/l; p = 0.006), and then persisted at the same levels throughout the rest of the study period. There was a slight but (..) (AU)</dc:description>
<dc:creator>Fernández-Ruiz, E. J</dc:creator>
<dc:creator>Páez, C</dc:creator>
<dc:creator>Martínez-Benavides, E</dc:creator>
<dc:creator>Martín-Herrera, C</dc:creator>
<dc:creator>Pino, M. D. del</dc:creator>
<dc:creator>Remón, C</dc:creator>
<dc:creator>Martínez-González, J. M</dc:creator>
<dc:creator>Montes, R</dc:creator>
<dc:creator>Torán, D</dc:creator>
<dc:creator>Pérez-Bañasc, V</dc:creator>
<dc:creator>Ruiz, A</dc:creator>
<dc:creator>Benítez, M</dc:creator>
<dc:creator>Tejuca, F</dc:creator>
<dc:creator>Guerrero, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El propósito de este estudio ha sido analizar la experiencia clínica con icodextrina en nuestra comunidad, especialmente la incidencia de efectos secundarios y la repercusión en el peso y lípidos plasmáticos a medio plazo al disminuir la carga de glucosa. La muestra estaba formada por 51 pacientes; edad57 ± 18 años (18-86), 30 mujeres y 21 hombres; tiempo icodextrina 10,3 ± 7meses (0-41); 21 en DPCA y 30 con cicladora. Además de los datos clínicos en relación con los efectos secundarios, se observó la evolución de diversos parámetros bioquímicos en el período basal (antes de icodextrina) y a los 6, 12 y18 meses. En 12 pacientes se estudiaron la ultrafiltración y aclaramientos de (..) (AU)</dc:description>
<dc:source>Nefrologia;21(6): 574-580, nov.-dic. 2001. tab</dc:source>
<dc:identifier>ibc-126487</dc:identifier>
<dc:title xml:lang="es">Experiencia clínica con icodrextrina. Estudio multicéntrico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29504^s22045</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d50497^s22067</dc:subject>
<dc:subject>^d23497^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23606^s22079</dc:subject>
<dc:subject>^d23861</dc:subject>
<dc:subject>^d29640</dc:subject>
<dc:subject>^d7189^s22080</dc:subject>
<dc:type>article</dc:type>
<dc:date>200112</dc:date>
</metadata>
</record>
</ibecs-document>
